Logo
x

Search

Subscribe Now

head and neck

GSK Discontinues the P-II Trials of Feladilimab for Advanced or Metastatic Head and Neck Squamous Cell Carcinoma

GSK Discontinues the P-II Trials of Feladilimab for Advanced or Metastatic Head and Neck Squamous Cell Carcinoma

  • April 16, 2021
Merus’ Petosemtamab Receives the US FDA’s Breakthrough Therapy Designation for Head and Neck Squamous Cell Carcinoma

    Merus’ Petosemtamab Receives the US FDA’s Breakthrough Therapy Designation for Head and Neck Squamous Cell Carcinoma

    • May 14, 2024
    PureTech’s LYT-200 Gains the US FDA’s Fast Track Designation for Treating Head and Neck Cancers

      PureTech’s LYT-200 Gains the US FDA’s Fast Track Designation for Treating Head and Neck Cancers

      • April 11, 2024
      Rapt Therapeutics Reports the P-II Study Results of Tivumecirnon Plus Keytruda for Treating Head and Neck Cancer

        Rapt Therapeutics Reports the P-II Study Results of Tivumecirnon Plus Keytruda for Treating Head and Neck Cancer

        • April 10, 2024
        PDS Biotech Reports Updated Interim Results from the P-II Trial (VERSATILE-002) Results of PDS0101 + Keytruda for Head and Neck Cancer

          PDS Biotech Reports Updated Interim Results from the P-II Trial (VERSATILE-002) Results of PDS0101 + Keytruda for Head and Neck Ca...

          • October 4, 2023
          Merck and Eisai Discontinue P-III Trial (LEAP-010) of Keytruda + Lenvima for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

            Merck and Eisai Discontinue P-III Trial (LEAP-010) of Keytruda + Lenvima for Recurrent or Metastatic Head and Neck Squamous Cell C...

            • August 28, 2023
            Ultimovacs Reports the Completion of Patient Enrolment in P-II Study (FOCUS) of UV1 for Head and Neck Cancer

              Ultimovacs Reports the Completion of Patient Enrolment in P-II Study (FOCUS) of UV1 for Head and Neck Cancer

              • August 3, 2023
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.